CSL commits $2.1b to expand Illinois manufacturing facility
Make us a preferred source
Make us a preferred source on Google
The news: CSL has committed to a USD1.5 billion ($2.12 billion) expansion of its Illinois plasma therapy manufacturing facility, which it broke ground on Monday.
The numbers: The Kankakee facility expansion is expected to be operational by 2031 and create at least 300 new jobs.
The context: The facility expansion will “substantially increase” CSL’s production of “life-sustaining, plasma-derived therapies for people living with rare and serious diseases and other acute medical issues”, according to the company.
A CSL spokesperson told Capital Brief that once the facility is complete, it will enable end-to-end manufacturing of immunoglobulin products within the US, replacing the need to process plasma at CSL’s Broadmeadows facility in Victoria or sites in Europe.
However, they noted that some other plasma therapies for US patients would still be processed at facilities outside the US. The company does not expect overall processing volumes at Broadmeadows to be impacted.
The expansion was announced by Illinois governor JB Pritzker and Illinois state senator Patrick Joyce alongside other officials.
This builds on the USD3 billion that CSL has already invested in the US since 2018. The USD1.5 billion investment in the US was approved in November 2025 but the business did not disclose where the funds would flow at the time.
The spokesperson also told Capital Brief that planning for the Illinois facility expansion “was in train before the US proposed a new regime of tariffs”.
What they said: “As the need for plasma-derived therapies continues to grow in the U.S. and globally, expanding our Kankakee site further strengthens this key hub in our supply network,” CSL interim CEO and managing director Gordon Naylor said.
“We thank our partners in government and our local community for supporting our mission to serve those who require these essential medicines.”
Pritzker said: “Illinois is leading the way in life sciences manufacturing, and CSL’s USD1.5 billion investment is a powerful vote of confidence in our state.
“This expansion will create hundreds of good-paying jobs and strengthen domestic supply chains for critical therapies. CSL’s continued growth in Kankakee County builds on decades of innovation and manufacturing leadership right here in Illinois.”
The source: CSL media release
